Ignite Creation Date:
2024-05-06 @ 8:27 AM
Last Modification Date:
2024-10-26 @ 12:00 PM
Study NCT ID:
NCT02747355
Status:
UNKNOWN
Last Update Posted:
2019-01-18
First Post:
2016-04-19
Brief Title:
Expression of Different Proliferation Biomarkers in Adreno-cortical Tumors
Sponsor:
Bnai Zion Medical Center
Organization:
Bnai Zion Medical Center
Study Overview
Official Title:
Expression of Different Proliferation Biomarkers in Adreno-cortical Tumors
Status:
UNKNOWN
Status Verified Date:
2019-01
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In adrenal tumors the investigators will examine if there is any correlation between WIESS criteria prognosis of the tumor and the different labeling index of the following proliferation biomarkers MCM3 MCM2 KI-67 P53 NEUROPILIN -1 METALLOTHIONEIN SEMAPHORIN-3A
Detailed Description:
One of the problems in managing adrenocortical tumors is the ability to distinguish between benign and malignant tumors while needle biopsy is unable to distinguish between the two situations Therefore when imaging tests demonstrate a suspected malignant adrenal tumor surgical excision of the tumor is needed Usually the histological WIESS criteria are used in order to determine malignancy However there are cases when adrenal tumors were defined by WIESS criteria as benign but metastasized later Moreover there is no reliable test than can determine prognosis KI-67 labeling index is a proliferation biomarker which is used to tell more about the malignant potential and prognosis of adrenal carcinoma
In various types of tumors proliferation biomarkers are used in attempt to tell about prognosis In this study the investigators will examine whether some biomarkers can differentiate between adrenal carcinoma and adenoma and if the degree of expression of these markers is correlated with prognosis
The investigators will retrospectively collect 30 cases of adrenal carcinoma 30 cases of adrenal adenoma and 10 cases of normal adrenals All specimens are preserved with formalin The investigators will re-review the WIESS criteria and all samples will be analyzed for the index labeling of the following proliferation biomarkers MCM3 MCM2 KI-67 P53 NEUROPILIN -1 METALLOTHIONEIN SEMAPHORIN-3A The investigators will examine if there is any correlation between the labeling index of each biomarker WIESS criteria and prognosis of the tumor
In various types of tumors proliferation biomarkers are used in attempt to tell about prognosis In this study the investigators will examine whether some biomarkers can differentiate between adrenal carcinoma and adenoma and if the degree of expression of these markers is correlated with prognosis
The investigators will retrospectively collect 30 cases of adrenal carcinoma 30 cases of adrenal adenoma and 10 cases of normal adrenals All specimens are preserved with formalin The investigators will re-review the WIESS criteria and all samples will be analyzed for the index labeling of the following proliferation biomarkers MCM3 MCM2 KI-67 P53 NEUROPILIN -1 METALLOTHIONEIN SEMAPHORIN-3A The investigators will examine if there is any correlation between the labeling index of each biomarker WIESS criteria and prognosis of the tumor
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None